Chairman of The State Pharmaceutical Group: The new crown inactivated vaccine is expected to be on the market by the end of the year, with two injections of less than one thousand yuan.

"I got two new coronary pneumonia vaccines and there were no adverse reactions.
, party secretary and chairman of China Pharmaceutical Group Co., Ltd. (hereinafter referred to as "National Pharmaceutical Group"), said.
, the new crown inactivated vaccine production workshop of China Bio-Beijing Biological Products Research Institute of China Pharmaceutical Group has met the conditions for use through joint biosecurity inspection organized by relevant state departments.
vaccine is the "killer" to overcome the new crown pneumonia epidemic, people have been looking forward to.
currently, how is the development of the new coronary pneumonia vaccine progressing? When will energy come on the market? Is it expensive? What is the effectiveness? The reporter interviewed Liu Jingxuan around the relevant hot issues. the
inactivated vaccine is expected to be available by the end of December, with an annual output of more than 200 million doses" new coronary pneumonia vaccine research actually has five routes, namely, the whole virus inactivated vaccine, the genetically engineered sub-unit vaccine, the adenovirus vector vaccine, the detoxifying influenza virus vector vaccine, and the nucleic acid vaccine.
, nucleic acid vaccines are mRNA and DNA vaccines.
" Liu Jingxuan introduced, after the outbreak, the National Pharmaceutical Group focused on the whole virus inactivated vaccine and genetic engineering sub-unit vaccine two routes to make key breakthroughs.
Among them, two units of China Bio-Wuhan Biological Products Research Institute and Beijing Bio-Products Research Institute of China Pharmaceutical Group conduct parallel research on inactivated vaccine routes, while China Biotechnology Research Institute of China Pharmaceutical Group conducts research on genetic engineering sub-unit vaccines.
Liu Jingxuan said that inactivated vaccine, simply said, is to first isolate the virus strain, like the selection of "seeds", you have to choose a good "seed", and then breeding culture, such as magnifying dozens of times, hundreds of times, and so on, and then kill these live viruses, so that it loses its infectious and replicable power, but at the same time retain it stimulates the body to produce immune response part of the function, and finally after purification and other processes into a vaccine.
, inactivated vaccines are developed faster, but at great investment.
, China National Pharmaceutical Group has invested about 2 billion yuan to build two P3 (three levels of biosecurity) production workshop.
February 16, we have followed international practice to conduct immunogenic studies on vaccine immunogenicity in seven experimental animals, including rats, mice, guinea pigs, rhesus monkeys, crab-eating monkeys and rabbits, to verify the effectiveness of the vaccine.
, we started small-scale human testing, and then we went to clinical studies.
" Liu said, clinical studies are usually divided into three phases.
, the first phase mainly evaluates vaccine safety, the second phase mainly evaluates vaccine safety and immunogenicity, and explores the immunization procedure, and the third phase evaluates the safety and ability of vaccine in a larger population.
April 12, Wuhan Institute of Biological Products developed a new corona inactivated vaccine into the first and second phase of clinical research, June 16 announced the clinical trial phase blinding results, the results show that the safety after vaccination is good, no serious adverse reactions After different procedures and doses of vaccination, the inoculators produced high-titration antibodies, and on April 27th, the inactivated vaccine developed by the Beijing Institute of Biological Products entered clinical study, and on June 28th the results of clinical phase I and II were announced.
23, the National Pharmaceutical Group launched an international clinical Phase III trial in the United Arab Emirates.
means that China is at the forefront of the world in the technical route of the new coronavirus inactivated vaccine.
, an inactivated vaccine, is ready for approval after the international clinical phase III trial is completed and is expected to be available by the end of December.
estimates that the annual production of inactivated vaccines at the Beijing Institute of Biological Products will reach 120 million doses, and the annual production of inactivated vaccines at the Wuhan Institute of Biological Products will reach 100 million doses.
addition, the genetically engineered sub-unit vaccine is expected to enter clinical research in October and, once successfully developed, can be produced quickly and in large quantities.
two-shot vaccine protection rate of 100%, the price of less than 1000 yuan in addition to focusing on the progress of vaccine research and development, people are also concerned about the price of vaccines.
, is inactivated vaccine expensive? "After the inactivated vaccine is on the market, the price will not be very high, it is expected that a few hundred dollars a shot.
if you take two injections, the price should be less than 1000 yuan.
" Liu Jingxuan told reporters that a shot of vaccine, the protection rate is about 97%, antibody production is slow, like a curve in slow growth, in general about half a month can reach the level of resistance to the new coronavirus;
Liu Jingxuan introduced, the first shot vaccine and the second shot time interval is generally 28 days, but in special circumstances can be played at the same time, left arm one shot, right arm one shot.
dose of the vaccine is 4 micrograms.
"Not everyone in our country needs to fight, such as students living in densely populated cities, office workers, etc., and people living in sparsely populated rural areas can not fight."
," Liu said.
to open full horsepower, as soon as possible to let people use the vaccine with confidence" the new coronavirus is the first time in the world, our understanding of it is very limited, its infectious, pathogenic, toxicity and so on are no reference standards.
even for such a new virus, we have to develop a safe and effective vaccine in the shortest possible time.
" Liu said that so far, vaccine research and development, clinical trials, production facilities and other related work is progressing smoothly, the future to open full horsepower, intensive testing, as soon as possible to let the people use the vaccine at ease.
the outbreak exposed some short-term problems, Liu Jingxuan suggested that the epidemic prevention and control of scientific and technological strength and scientific research capabilities into the reserve.
actively carry out joint research and technology sharing, use cutting-edge technology to drive emergency reserve capacity-building, set up a major special fund for vaccine research and development, continue to increase support for vaccine research and development enterprises, promote the development and innovation of the vaccine industry, enhance the overall strength of vaccine "Made in China" and international competitiveness.
the same time, strengthen the construction of biosecurity system.
to include vaccines and blood products in the scope of national biosecurity, further improve the status of biosecurity, promote the biological products industry research and development, production scale, intensive, immunization planning vaccine production, centralized distribution.
Liu Jingxuan believes that in order to face the needs of public health system construction, according to the disaster situation, epidemic and emergency new situation, new problems, revise and improve the relevant laws and regulations, the introduction of existing laws and regulations, the introduction of special regulations and regulations, so that emergency medical supplies to ensure that the law can be followed.
Focus on the production, storage, mining, supply of the four main links of the short board, give full play to the role of the core link of information, the establishment of central, local, enterprise unified leadership, hierarchical division of labor, coordination, dynamic adjustment of the emergency materials security system.
" to improve the national central reserve category, reasonable allocation of reserve scale structure.
" Liu said, carry out demand analysis based on risk assessment, expand the classification and product catalog of central reserve materials, optimize the reserve structure, scientifically adjust the variety and quantity of reserves;
.